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INTRODUCTION 
One of the most important issues for treating patients with 
early stage breast cancer is determining those who could bene- 
fit from adjuvant chemotherapy and which chemotherapy 
regimen would provide the best results. Prognostic factors can 
be used to predict the natural history of breast cancer, so they 
are included in the decision to apply adjuvant systemic che-
motherapy for patients with breast cancer. Currently, the pres-
ence of axillary lymph node involvement, tumor size, nuclear 
grade, hormone receptor status, and patient age are well-known 
prognostic factors for patients with operable invasive breast 
cancer [1]. These prognostic factors are widely used to deter-
mine whether to apply adjuvant chemotherapy in patients with 
breast cancer. Among the prognostic factors, axillary lymph 
node involvement is the most significant [1,2]. Because the 
presence of lymph node involvement shows that the cancer 
has already developed the ability for distant metastasis [2-4]. 
Thus, the presence of axillary lymph node involvement pre-
dicts the choice of adjuvant chemotherapy and radiation ther-
apy after surgery for primary breast cancer [5].
Lymphovascular invasion (LVI) is defined as tumor emboli 
present within a definite endothelial-lined space in the breast 
surrounding invasive carcinoma [6,7]. The existence of LVI 
may help identify who is at increased risk for axillary lymph 
node and distant metastasis [2,3] Although LVI has been ac-
cepted as an important prognostic factor in patients with lymph 
node-negative invasive breast cancer [8], LVI is controversial 
regarding prognostic value in patients with lymph node-posi-
tive breast cancer [3,9-11]. The aim of this study was to ana-
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Purpose: Lymphovascular invasion (LVI) is an important prognostic 
factor in patients with lymph node-negative patients with inva-
sive breast cancer. However, the prognostic value of LVI it is un-
clear and controversial about its prognostic value in patients with 
lymph node-positive breast cancer patients. So, we report the 
an analysis of the prognostic significance of LVI in a large cohort 
study of patients with lymph node-positive patients with invasive 
breast cancer. Methods: We retrospectively reviewed 967 patients 
with invasive breast cancer that had undergone surgical treatment 
at our hospital, from January 2004 to December 2007. Among 
these thempatients, 349 patients with lymph node-positive breast 
cancer patients are were included in this study. We evaluated 
clinical and pathological data in these patients, we compared 
with 5-year overall survival and disease-free survival between an 
LVI-present group and an LVI-absent group. Results: The median 
follow-up was 48 months (range, 12-78 months), and the mean 
age of the patients was 48 years (range, 23-78 years). LVI was 
present in 192 patients (55%) of with tumors and was associated 
with age ≤40 years (p=0.009), high histologichistological grade 
(p=0.007), estrogen receptor status (p=0.001), tumor size ≥2 cm 
(p<0.001), and number of involved lymph nodes (p<0.001), but 
not with progesterone receptor status, HER2 status, p53 status, 
or tumor multiplicity. LVI was a significant independent prognos-
tic factor for disease-free survival (p<0.001) and overall survival 
(p=0.006). By multivariate analysis revealed that LVI (p=0.003), 
number of involved lymph nodes (≥4; p=0.005), and high histo-
logical grade (II and III; p=0.02) was were an independent signif-
icant predictors of disease-free survival and overall survival in the 
whole group of patients. Conclusion: In this case, we demonstrated 
that LVI is a significant predictor of poor prognosis in patients with 
lymph node-positive patients with primary invasive breast cancer, 
LVI is a significant predictive predictor value of poor prognosis. So, 
LVI should be considered in the therapeutic strategy as a decision 
making tool in the adjuvant chemotherapy setting.
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lyze the prognostic significance of LVI in a large cohort study 
of patients with lymph node-positive invasive breast cancer.
METHODS
Patients and methods
From January 2004 to December 2007, we retrospectively 
reviewed 989 patients with invasive breast cancer that had un-
dergone surgical treatment at the Department of Surgery, 
Chonnam National University Hospital. In total, 596 lymph 
node-negative and 371 lymph-node positive patients were en-
rolled. Among the 371 lymph-node positive patients, 22 (six 
patients with a previous or a concurrent contralateral breast 
cancer, two males with breast cancer, and 14 patients who un-
derwent neoadjuvant chemotherapy) were excluded. Thus, 
349 patients with lymph node-positive breast cancer were in-
cluded. Among the 349 patients, 11 were treated with sentinel 
lymph node biopsy only because the frozen biopsy was nega-
tive, whereas permanent sections revealed positive findings. 
We evaluated the 349 patients with lymph-node positive in-
vasive breast cancer during a mean follow-up of 48 months 
(range, 12-78 months). These patients had been surgically 
treated with either a modified radical mastectomy or wide lo-
cal tumor resection, with sentinel lymph node biopsy or axil-
lary lymph node dissection, followed by postoperative radia-
tion therapy. The need for adjuvant systemic therapy (chemo-
therapy and hormonal therapy) was determined according to 
axillary lymph node status, hormone receptor status, and meno-
pausal status. All patients visited the hospital every 6 months 
for 5 years, then once per year. 
Pathologic examination
We analyzed the patient’s clinicopathological data including 
age, tumor size, hormone receptor status, axillary lymph node 
status, nuclear grade, and presence of LVI. Diameter of the tu-
mor was measured on pathological specimens that were he-
matoxylin and eosin (H&E) stained. Nuclear grade was iden-
tified by a modified Scarff–Bloom–Richardson grading sys-
tem. Lymph nodes were stained with H&E and examined for 
tumor cell metastasis. Hormone receptor (estrogen [ER] and 
progesterone [PR] receptors) and HER2 status was determined 
by immunohistochemical (IHC) analysis using a tissue micro-
array [13]. The immunohistochemical analyses used an ER 
antibody (1D5; DAKO, Carpinteria, USA), a PR antibody 
(PgR636; DAKO), and a HER2 antibody (4B5; DAKO). Hor-
mone receptors were considered positive if expression was 
≥10%. The HER2 expression results by IHC analysis were 
scored as negative, 1+, 2+, or 3+, according to the manufac-
turer’s recommendations. Patients with a score of 3+ were con-
sidered HER2 positive. HER2/chromosome 17 fluorescence 
in situ hybridization was performed on patients in which the 
IHC analysis score was 2+. 
LVI was assessed on H&E-stained slides, as defined by Rosen 
and Oberman [6]. LVI was defined as carcinoma cells present 
within a definite endothelial-lined space, at a distance from 
the tumors, in the breast surrounding the invasive carcinoma.
[6-8] That is, LVI must be assessed outside the boundaries of 
the main breast tumor (at least more than one high power   
microscopic field away) to avoid misinterpretation [9]. When 
interpretation results were vague, the immunostaining mark-
ers D2-40 and CD34 were used to confirm that LVI by H&E 
staining was truly present. 
The clinicopathological data and systemic or locoregional 
Table 1. Clinicopathological data of patients
Patient characteristic
LVI negative
No. (%)
(n=157)
LVI positive
No. (%)
(n=192)
Total
No. (%)
p-value
Age (yr)       0.009
   ≤40 21 (30.9) 47 (69.1) 68 (19.5)
   >40 136 (48.4) 145 (51.6) 281 (80.5)
Tumor size (mm)       <0.001
   ≤10 13 (54.2) 11 (45.8) 24 (6.9)
   10>, ≤20 69 (65.1) 37 (34.9) 106 (30.4)
   >20 75 (34.2) 144 (65.8) 219 (62.8)
Multiplicity       NS
   Single 149 (44.6) 185 (55.4) 334 (95.7)
   multiple 8 (53.3) 7 (46.7) 15 (4.3)
Grade       0.007
   I 29 (58.0) 21 (42.0) 50 (14.3)
   II 86 (48.6) 91 (51.4) 177 (50.7)
   III 42 (34.4) 80 (65.6) 122 (35.0)
No. of positive LN       <0.001
   1 64 (64.3) 37 (36.6) 101 (28.9)
   2 31 (50.8) 30 (49.2) 61 (17.5)
   3 14 (45.2) 17 (54.8) 31 (8.9)
  ≥4 48 (30.8) 108 (69.2) 156 (44.7)
ER       0.001
   Negative 54 (35.3) 99 (64.7) 153 (43.8)
   Positive 103 (52.6) 93 (48.4) 196 (56.2)
PR       NS
   Negative 89 (43.2) 117 (56.8) 206 (59)
   Positive 68 (47.6) 75 (52.4) 143 (41)
Hormonal receptors       0.005
   ER and PR negative 46 (35.4) 84 (64.6) 130 (37.2)
   ER or PR positive 111 (50.7) 108 (49.3) 219 (62.8)
HER2 status       NS
   Negative 124 (46.8) 141 (53.2) 265 (76.1)
   Positive 32 (38.6) 51 (61.4) 83 (23.9) 
p53       NS
   Negative 66 (44.6) 82 (55.4) 148 (45.7)
   Positive 76 (42.9) 100 (57.1) 176 (54.3)
LVI=lymphovascular invasion; NS=not significant; LN=lymph node; ER= 
estrogen receptor; PR=progesterone receptor. 200   Young Ju Song, et al.
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treatment of the 349 patients are summarized in Tables 1 and 
2. Clinicopathological data were analyzed according to the 
presence of LVI to establish the relationship between LVI and 
other factors.  
Statistical analysis 
Correlations between LVI and patient clinicopathological 
data were analyzed with the chi-square test. Overall survival 
(OS), disease-free survival (DFS), and metastasis-free survival 
(MFS) rates were evaluated using the Kaplan–Meier method 
from the date of surgery to death, recurrence, or distant meta-
stasis. Univariate analyses were performed with the log-rank 
test. Multivariate analyses were performed using the Cox re-
gression model. A p-value<0.05 was considered significant.
RESULTS
The mean age of the patients at the time of surgery was 48 
years (range, 23-78 years), and the median follow-up period 
was 48 months (range, 12-78 months). The number of distant 
metastases with or without locoregional recurrence was 61 
(17.5%). The number of locoregional recurrences or distant 
metastases was 72 (20.9%). Thirty-six of 343 (10.3%) patients 
died because of breast cancer at the time of the study. Five-year 
OS, MFS, and DFS were 93%, 89.1%, and 87%, respectively. 
LVI was present in 192 of 349 (55%) patients and was sig-
nificantly associated with patient age ≤40 years (p=0.009), 
high histological grade (grades II and III, p=0.007), tumor 
diameter >20 mm (p=0.001), number of involved lymph 
nodes ≥4 (p=0.001), and negative ER (p=0.001) tumors. 
But it was not related to tumor multiplicity, PR status, HER2 
receptor status, or p53 status (Table 1). Patients with negative 
LVI tumors were more frequently treated with adjuvant endo-
crine therapy (52.5% vs. 47.5, p=0.001). Surgical treatment 
and adjuvant chemotherapy were not significantly associated 
with the presence of LVI (Table 2). 
In a univariate survival analysis, both 5-year OS and 5 year 
DFS were significantly different in patients with or without 
LVI: 88.8% vs. 94.1% (p=0.007) for OS (Figure 1A) and 76.4% 
vs. 90.9% (p<0.001) for DFS (Figure 1B). Furthermore, 5-year 
MFS was shorter in patients with LVI: 80.1% vs. 91.5% than 
those without LVI (p<0.001) (Figure 2).
In the univariate analysis, presence of LVI, tumor size (>20 
mm), high histological grade (grades II and III), number of 
involved lymph nodes (≥4), hormone receptor status (nega-
tive ER and PR), and HER2 receptor status (positive) were as-
sociated with poor DFS. But age, tumor multiplicity, and p53 
status did not influence DFS (Table 3). 
 LVI was an independent prognostic factor for DFS in all 
patients (relative risk [RR], 2.59; 95% confidence interval [CI], 
1.35-5.53; p=0.005). Furthermore, histological grade II (RR, 
Table 2. Locoregional and systemic adjuvant therapy
Therapy
LVI negative
No. (%)
(n=157)
LVI positive
No. (%)
(n=192)
Total
No. (%) 
p-value
Surgery     NS
   MRM only 38 (45.8) 45 (54.2) 83 (23.8)
   MRM+RT 45 (36.9) 77 (63.1) 122 (35.0)
   BCS+RT 74 (51.4) 70 (48.6) 144 (41.3)
Systemic treatment      
   Chemotherapy  152 (44.4) 190 (55.6) 342/349 (98) NS
   Hormone therapy 106 (52.5) 96 (47.5) 202/349 (58.2) 0.001
LVI=lymphovascular invasion; MRM=modified radical mastectomy; RT= 
radiotherapy; BCS=breast conserving surgery; NS=not significant.  
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Figure 1. Overall survival and disease-free survival of whole patients. (A) Overall survival curves are shown according to presence or absence of lym-
phovascular invasion (LVI). (B) Disease-free survival curves according to presence or absence of LVI are shown. Prognostic Factor in Lymph Node-Positive Breast Cancer 201
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3.20; 95% CI, 1.00-10.65; p=0.049), histological grade III (RR, 
4.12; 95% CI, 1.25-13.57; p=0.02), and a high number of in-
volved lymph nodes (≥4; RR, 2.73; 95% CI, 1.35-5.53; p= 
0.003) were independent predictors in all patients. However, 
age, tumor size, hormone receptor status, and HER2 status 
were not significant independent factors (Table 4).  
In the hormone receptor-positive group (n=218), positive 
LVI (p=0.021), number of involved lymph nodes (p=0.037) 
and histological grade III (p=0.023) were also independent 
factors for a poor prognosis (Table 5).
DISCUSSION
Previous well-designed studies have analyzed the prognos-
tic factors in patients with invasive breast cancer. Axillary lymph 
node involvement, younger age, high histological grade, large 
tumor size, and negative hormone receptor status were signifi-
cantly associated with a poor prognosis (DFS and OS) [1]. Pre-
vious studies have also shown that LVI is an independent poor 
prognostic factor in patients with invasive breast cancer [2,3,14]. 
Nevertheless, although LVI is an important prognostic factor 
in patients with lymph node-negative invasive breast cancer, 
its prognostic value in patients with lymph node-positive breast 
cancer is unclear and controversial [3,9-11]. So, we report the 
analysis of the prognostic significance of LVI in a large cohort 
Table 3. Univariate analysis of disease-free survival and clinicopatholog-
ical data
Patient characteristics No. (%) 5-yr DFS (%) p-value
LVI     <0.001
   Negative 155 (45) 90.9
   Positive 188 (55) 76.4
Age (yr)     0.099
   ≤40 67 (19.5) 64.9
   >40 276 (80.5) 85.4
Tumor size (mm)     0.002
   ≤10 23 (6.9) 95.7
   10-20 105 (30.4) 88.6
   >20 215 (62.8) 79.4
Multiplicity     NS
   Single 329 (95.7) 86.8
   Multiple 14 (4.3) 75.7
Grade     0.004
   I 49 (14.3) 92.6
   II 174 (50.7) 83.1
   III 120 (35) 69.9
No. of positive LN     <0.001
   1 99 (28.9) 88.3
   2 61 (17.5) 85.3
   3 30 (8.9) 79.8
   >4  153 (44.7) 70.8
ER     0.023
   Negative 151 (43.8) 75.4
   Positive 192 (56.2) 86.3
PR     0.006
   Negative 204 (59) 79.1
   Positive 139 (41) 86.7
HER2 status     0.032
   Negative 260 (75.9) 86.4
   Positive 82 (23.8) 69.6
p53    
   Negative 146 (42.4) 83.6 NS
   Positive   172 (50.4) 78.8
DFS=disease-free survival; LVI=lymphovascular invasion; NS=not significant; 
LN=lymph node; ER=estrogen receptor; PR=progesterone receptor. 
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Figure 2. Metastasis-free survival of whole patients. Metastasis-free 
survival curves are shown according to presence or absence of lym-
phovascular invasion (LVI).
Table 4. Disease-free survival: multivariate analysis in the whole group 
of patients
Patient characteristic RR 95% CI p-value
≥4 involved LN 2.737 1.352-5.539 0.005
Grade II 3.207 1.004-10.650 0.049
Grade III 4.127 1.253-13.587 0.020
LVI 2.594 1.384-4.862 0.003
RR=relative risk; CI=confidence interval; LN=lymph node; LVI=lymphovas-
cular invasion.
Table 5. Disease-free survival: multivariate analysis in the hormone re-
ceptor-positive group of patients
Patient characteristic RR 95% CI p-value
≥4 involved LN 2.688 1.064-6.792 0.037
Grade III 5.712 1.277-25.544 0.023
LVI 2.489 1.147-5.398 0.021
RR=relative risk; CI=confidence interval; LN=lymph node; LVI=lymphovas-
cular invasion. 202   Young Ju Song, et al.
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study of lymph node-positive patients with invasive breast 
cancer.
In our retrospective study, LVI was observed in 55% (n=192) 
of all patients (n=349), which was similar to other series of 
lymph node-positive cancer. LVI added prognostic informa-
tion for patients with lymph node-positive breast cancer with 
a RR of 2.59 and a p-value of 0.003. These results contrast 
with those reported by Colleoni et al. [10] This discrepancy 
may be explained by the short-term follow-up period and 
analysis limitations in patients with 1 to 3 metastatic lymph 
nodes in their study. 
In addition to LVI, our study demonstrated that high histol- 
ogical grade, number of lymph nodes involved, and both fac-
tors constituting the Nottingham Prognostic Index were other 
significant independent clinicopathological factors. Because 
LVI appears to be independent from these pathological factors, 
our results propose that LVI should be considered in the prog-
nostic index for patients with lymph node-positive breast can-
cer as well as in the group of patients with lymph node-nega-
tive breast cancer [15]. However, tumor size and patient age 
were not significant independent prognostic factors in our 
study. This result may be explained by the shorter follow-up 
period compared to that in previous studies. 
We also assessed whether LVI had an effect on the hormone 
receptor-positive subgroup of patients as an independent prog-
nostic factor. This analysis was restricted to the large subgroup 
of 218 patients who were hormone receptor-positive. In this 
subgroup, with a RR of 2.48 and a p-value of 0.021, LVI was an 
significant prognostic factor in patients who were hormone 
receptor-positive. These results suggest that LVI and other 
pathological factors may be useful to determine the need for 
adjuvant treatment in some patients for whom adjuvant che-
motherapy could be dangerous despite axillary lymph node in-
volvement. Eventually this may be applicable to the elderly or 
fragile patients (patients with severe underlying disease) with 
other treatment options such as endocrine and trastuzumab 
therapy.
Our analysis had three limitations. First, our analysis had a 
short follow-up period, and it was retrospective in nature. Sec-
ond, not all patients with HER2-positive breast cancer were 
treated with a trastuzumab-based regimen. Third, LVI was as-
sessed by H&E staining, and the selective endothelial cell mark-
ers such as D2-40, CD34 were not used in the routine patho-
logical evaluation, but use of such markers could potentially 
have improved the accuracy of detecting LVI [16].  
In conclusion, this study emphasized the role of pathologic-
almetastasis analysis in the prognostic evaluation of breast 
cancer, particularly those factors that cannot be subjected to 
molecular analyses, such as size, lymph node status, histologi-
cal grade, and LVI. These pathological factors are useful to 
evaluate prognostic and predictive factors for more effective 
and convenient clinical decision-making tools during adju-
vant treatment. 
The presence of LVI was an independent significant prog-
nostic factor in patients with lymph node-positive breast can-
cer as well as patients with lymph node-negative breast cancer. 
The existence of LVI alone cannot be used to decide to omit 
adjuvant chemotherapy in all patients with lymph-node posi-
tive breast cancer but, it may be considered in the adjuvant 
treatment decision in a specific subgroup of patients for whom 
chemotherapy is contraindicated. We suggest that patients with 
LVI-positive breast cancer require a shorter follow up and ad-
ditional management. 
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